ACB — Aurora Cannabis Inc.

Aurora Cannabis Inc. Q3 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Net Revenue: Increased by 7% to $94.2 million, with global medical cannabis revenue growing 12% to $76.2 million.
• Adjusted Gross Margin: Rose by 100 basis points to 62%, with medical cannabis margins at 69%.
• Adjusted EBITDA: Reported at $18.5 million, slightly down from $19.4 million year-over-year.
• Adjusted Net Income: Stable at $7.2 million compared to $7.4 million in the prior year.
• Free Cash Flow: Positive at $15.5 million, down from $27.4 million year-over-year.
• Cash Position: Ended the quarter with $154 million in cash and no cannabis-related debt.

2. Strategic Updates and Business Highlights:

• Aurora is focusing on the global medical cannabis market, which it sees as the most promising segment.
• The company plans to exit select lower-margin Canadian consumer cannabis markets to reallocate resources to higher-margin medical cannabis operations.
• Aurora is divesting its controlling stake in Bevo, its plant propagation business, to streamline operations and enhance profitability.
• The company has established a new at-the-market equity program to raise up to $100 million for strategic investments, including cultivation capacity and potential M&A.

3. Forward Guidance and Outlook:

• For the fiscal year ending March 31, 2026, Aurora expects global medical cannabis net revenue to be between $269 million and $281 million, reflecting 10% to 15% growth.
• Consolidated adjusted EBITDA is projected to increase to between $52 million and $57 million, representing 5% to 10% annual growth.
• The company anticipates some one-time costs in Q4 related to market exits but expects improved adjusted EBITDA contributions thereafter.

4. Bad News, Challenges, or Points of Concern:

• Consumer cannabis revenue declined significantly by 48% year-over-year, reflecting the strategic shift away from this segment.
• Increased competition in the German market has led to price pressure, particularly in the value segment.
• The plant propagation segment's adjusted gross margin fell to 16%, down from 40%, due to rising costs and inventory write-offs.
• There are anticipated near-term pressures on sales and gross profit in Australia as the company transitions its product mix towards premium offerings.

5. Notable Q&A Insights:

• Management emphasized that exiting consumer cannabis markets will be beneficial for overall financial results, focusing on reallocating resources to international markets.
• The transition to premium products in Australia is expected to be non-disruptive and margin-accretive.
• The divestiture of the plant propagation business is seen as a strategic move to concentrate on high-growth medical cannabis markets.
• Management is optimistic about potential regulatory changes in the U.S. regarding cannabis rescheduling, which could open opportunities for Aurora, although specifics remain unclear.
• The company is exploring international markets for expansion, particularly in Europe, where they see strong growth potential.

Overall, Aurora Cannabis is positioning itself for sustainable growth in the medical cannabis sector while navigating challenges in consumer markets and competitive pressures.